Estimating vaccine effectiveness against COVID-19 using cause-specific sick leave as an indicator: a nationwide population-based cohort study, Norway, July 2021 – December 2022

Hinta Meijerink,Lamprini Veneti,Anja Bråthen Kristoffersen,Anders Skyrud Danielsen,Melanie Stecher,Jostein Starrfelt
DOI: https://doi.org/10.1186/s12889-024-19374-0
IF: 4.5
2024-07-14
BMC Public Health
Abstract:Due to changes in testing policy and increased use of rapid tests, other indicators for SARS-CoV-2 infections are needed to monitor vaccine effectiveness (VE). We aimed to estimate VE against COVID-19 sick leave (> 3 days, certified by a medical professional) among employed individuals (25–64-years-old) in Norway.
public, environmental & occupational health
What problem does this paper attempt to address?